Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed

Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.

Asia Deal Watch
Alamy • Source: Alamy

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

AffaMed Therapeutics unveiled a licensing agreement on 3 January with Hanmi Pharmaceutical Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal Watch

More from Deals